See more : Miko International Holdings Limited (1247.HK) Income Statement Analysis – Financial Results
Complete financial analysis of Ayala Pharmaceuticals, Inc. (AYLA) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Ayala Pharmaceuticals, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- Samor Reality Limited (SAMOR.BO) Income Statement Analysis – Financial Results
- Inception Growth Acquisition Limited (IGTAW) Income Statement Analysis – Financial Results
- Cyber Operations, Inc. (CYPJ) Income Statement Analysis – Financial Results
- CBRE Group, Inc. (CBRE) Income Statement Analysis – Financial Results
- Afdeling Peruma Invest Globale Aktier (IAIPGA.CO) Income Statement Analysis – Financial Results
Ayala Pharmaceuticals, Inc. (AYLA)
About Ayala Pharmaceuticals, Inc.
Ayala Pharmaceuticals, Inc., a clinical-stage oncology company, focuses on developing and commercializing small molecule therapeutics for patients suffering from rare and aggressive cancers. The company's lead product candidate is AL101, a potent, selective, and injectable small molecule gamma secretase inhibitor (GSI) that is in Phase II clinical trial for the treatment of recurrent/metastatic adenoid cystic carcinoma for patients bearing Notch-activating mutations. It is also involved in developing AL102, a potent, selective, and oral small molecule GSI that is in Phase II/III pivotal study for the treatment of desmoid tumors. Ayala Pharmaceuticals, Inc. has a collaboration agreement with Novartis International Pharmaceutical Limited to develop AL102 for the treatment of multiple myeloma. The company was incorporated in 2017 and is headquartered in Rehovot, Israel.
| Metric | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|
| Revenue | 692.00K | 0.00 | 3.71M | 2.33M | 0.00 |
| Cost of Revenue | 602.00K | 3.51M | 3.71M | 1.29M | 0.00 |
| Gross Profit | 90.00K | -3.51M | 0.00 | 1.05M | 0.00 |
| Gross Profit Ratio | 13.01% | 0.00% | 0.00% | 44.94% | 0.00% |
| Research & Development | 27.85M | 29.94M | 22.41M | 14.42M | 5.74M |
| General & Administrative | 9.74M | 9.28M | 7.37M | 4.34M | 3.29M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 9.74M | 9.28M | 7.37M | 4.34M | 3.29M |
| Other Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 37.59M | 39.22M | 29.78M | 18.76M | 9.04M |
| Cost & Expenses | 38.20M | 42.72M | 33.49M | 20.05M | 9.04M |
| Interest Income | 0.00 | 0.00 | 56.00K | 225.00K | 448.00K |
| Interest Expense | -74.00K | -1.55M | 56.00K | 225.00K | 0.00 |
| Depreciation & Amortization | 162.00K | 168.00K | 182.00K | 150.00K | 49.00K |
| EBITDA | -37.50M | -40.86M | -29.48M | -17.11M | -8.54M |
| EBITDA Ratio | -5,419.51% | 0.00% | -795.12% | -733.12% | 0.00% |
| Operating Income | -37.50M | -41.03M | -29.78M | -17.71M | -9.04M |
| Operating Income Ratio | -5,419.51% | 0.00% | -803.05% | -758.83% | 0.00% |
| Total Other Income/Expenses | 74.00K | 3.25M | 56.00K | 225.00K | 448.00K |
| Income Before Tax | -37.43M | -39.48M | -29.72M | -17.49M | -8.59M |
| Income Before Tax Ratio | -5,408.82% | 0.00% | -801.54% | -749.19% | 0.00% |
| Income Tax Expense | 584.00K | -776.00K | 425.00K | 306.00K | 286.00K |
| Net Income | -38.01M | -38.70M | -30.15M | -17.79M | -8.87M |
| Net Income Ratio | -5,493.21% | 0.00% | -813.00% | -762.30% | 0.00% |
| EPS | -2.46 | -3.92 | -3.06 | -2.07 | -1.31 |
| EPS Diluted | -2.46 | -3.92 | -3.06 | -2.07 | -1.31 |
| Weighted Avg Shares Out | 15.45M | 9.86M | 9.86M | 8.58M | 6.77M |
| Weighted Avg Shares Out (Dil) | 15.45M | 9.86M | 9.86M | 8.58M | 6.77M |
Ayala Pharmaceuticals (AYLA) Soars: Stock Adds 13.2% in Session
Ayala Pharmaceuticals to Present at Noble Capital Markets 17th Annual Small & Microcap Virtual Investor Conference
Ayala Pharmaceuticals to Present at the Virtual H.C. Wainwright Bioconnect Conference
Ayala Pharmaceuticals to Accelerate Development of AL102 for the Treatment of Desmoid Tumors in Pivotal Phase 2/3 Study
Is Ayala Pharmaceuticals, Inc. (AYLA) A Good Stock To Buy?
Ayala Pharmaceuticals Reports Third Quarter 2020 Financial Results and Provides Business Update
Ayala Pharmaceuticals to Participate in Upcoming Virtual Investor Conferences
Source: https://incomestatements.info
Category: Stock Reports